AstraZeneca updates its vaccine efficacy rate to 76% after reviewing its US study

AstraZeneca vaccine vials.

EAstraZeneca has updated the average efficacy rate of its Covid vaccine to 76% to prevent symptomatic diseases after review preliminary results of its phase III study carried out in the US, Peru and Chile, which showed 79%.

The average effectiveness rate is somewhat lower than advertised in the preliminary results released Monday by the company, although these three percentage points of difference are not very significant in terms of mean efficacy in a clinical trial.

To continue reading, go Premium from € 1 the first month

and enjoy unlimited access to all Expansión web content

Already Premium? Your inicie voice

.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.